Global /China /Healthcare /Drug Manufacturers - General /300254
chevron_leftBack
ShanXi C&Y Pharmaceutical Group Co.,LTD. logo

ShanXi C&Y Pharmaceutical Group Co.,LTD.

300254
SHE: 300254 Delayed
13.50CNY 5.4%
1.99 USD
As of 24 June 2026, ShanXi C&Y Pharmaceutical Group Co.,LTD. has a market cap of $483.51M USD, ranking #15338 globally and #4805 in China. It ranks #1364 in the Healthcare sector, and #504 in the Drug Manufacturers - General industry.
Global Rank
15338
Country Rank
4805
Sector Rank
1364
Industry Rank
504
Key Stats
Market Cap
$483.51MUSD
3.28B CNY
Enterprise Value
$559.57MUSD
3.79B CNY
Revenue (TTM)
$125.19MUSD
849.26M CNY
EBITDA (TTM)
$18.55MUSD
125.57M CNY
Net Income (TTM)
$3.0MUSD
20.36M CNY
EBITDA Margin
15%
Profit Margin
2.4%
PE Ratio
153.8
PS Ratio
3.9
PB Ratio
5.7
EV/EBITDA
28.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Qun Zhao open_in_new
Employees
1,196
Founded
2005
Website
cy-pharm.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
5.4% 14% 21% 29% 21% 56%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300254
山西仟源医药集团股份有限公司 Class A
ISIN: CNE1000016D0
Shares Out.:
244.189M1 Shares Float: 238.258M2
TV:
SA:
YF:
GF:
BA:
MS:
13.50 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ShanXi C&Y Pharmaceutical Group Co.,LTD.

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to ShanXi C&Y Pharmaceutical Group Co.,LTD. in September 2014. The company was founded in 2005 and is based in Datong, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.79B
364.89B CNY
11K%
44.9
603259
$49.58B
336.36B CNY
10K%
17.2
$28.5B
223.48B HKD
6K%
35.7
$18.79B
147.32B HKD
4K%
162.3
$16.49B
111.89B CNY
3K%
-
9926
$16.0B
125.46B HKD
3K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
157K%
38.1
JNJ
$547.28B
113K%
26.4
ABBV
$360.63B
74K%
97.4
$316.71B
256.25B CHF
65K%
19.9
AZN
$285.49B
215.59B GBP
59K%
27.6
MRK
$274.03B
57K%
15.1
chevron_leftBack